News | March 13, 2013

CircuLite Receives Conditional IDE Approval for Synergy Feasibility Trial

March 13, 2013 — CircuLite Inc. announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) for an investigational device exemption (IDE) for its lead product, the Synergy circulatory support system, a minimally invasive device designed to reverse the symptoms of heart failure in ambulatory chronic heart failure patients.

Heart failure is a progressive disease. Once patients deteriorate to the point of experiencing persistent, severe symptoms despite receiving optimal medical treatment (ACE inhibitor, beta blocker, defibrillator and/or pacemaker), their options are very limited. Synergy is the world’s smallest circulatory support pump — approximately the size and weight of a AA battery — and is designed to work in synergy with the native heart to improve blood flow to the brain and body, rather than replace the heart’s function. The procedure is minimally invasive and does not require open-heart surgery, eliminating the need for cardiopulmonary bypass. In a European CE mark clinical study, Synergy was shown to improve hemodynamics, exercise capacity and overall quality of life in ambulatory chronic heart failure patients (INTERMACS ?4 or NYHA Class III/IV).

“Many ambulatory chronic heart failure patients have a very poor quality of life today,” said Daniel Burkhoff, M.D., Ph.D., chief medical officer of CircuLite and adjunct associate professor of medicine at Columbia University Medical School. “Despite running the gamut of heart failure treatment, they are severely restricted by their symptoms, yet are not sick enough to justify more invasive surgical treatment options. Synergy has the potential to reverse many of the abnormalities that underlie those symptoms, with the goal of improving a patient’s activity level and quality of life.”

With receipt of conditional IDE approval, CircuLite plans to commence its U.S. clinical trial evaluating the use of the system for long-term support in ambulatory chronic heart failure patients (INTERMACS ?4) who remain symptomatic despite optimal medical management. The IMPACT (Safety EvaluatIon of the CircuLite SYNERGY Circulatory Assist Device in a Non-Inotrope Dependent, AMbulatory Patient with End-StAge Chronic Heart Failure: A PiloT Study) trial is a 20-patient feasibility trial that will be conducted at seven U.S. clinical sites.

“Beginning our U.S. feasibility trial marks a significant milestone for the company, and is the first step on our path to providing a new treatment option to tens of thousands of U.S. ambulatory chronic heart failure patients who have no other options today,” said Paul Southworth, CEO of CircuLite.

The minimally invasive Synergy procedure is performed through a mini-thoracotomy, and the micro-pump is implanted in a shallow “pacemaker pocket.” It requires no bypass and enables a quick recovery, offering the potential to impact the economics of treating ambulatory chronic heart failure patients.

Synergy received CE mark in September 2012 and is currently conducting a controlled commercial rollout in Europe.

The Synergy circulatory support system is a micro-blood pump that provides up to 4.25 liters of blood per minute and reduces the heart's workload while improving blood flow to vital organs. In addition, it is intended to reduce re-hospitalizations associated with heart failure symptoms. Synergy is designed and manufactured in Aachen, Germany.

For more information: www.circulite.net

Related Content

News | Heart Failure| November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Scientists Reverse Advanced Heart Failure in Mouse Model
News | Heart Failure| October 30, 2017
October 30, 2017 — Researchers have discovered a previously unrecognized healing capacity of the heart.
CorInnova Awarded Seminal Patent for Minimally Invasively-Delivered Soft Robotic Heart Device
News | Artificial Heart| October 27, 2017
CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its intellectual property...
Detroit Cardiogenic Shock Initiative Goes National at TCT 2017
News | Hemodynamic Support Devices| October 26, 2017
Medical professionals representing hospital systems from across the United States are expected to attend the first...
Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Overlay Init